ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Pharmacokinetics of AFQ056 in Subjects With Hepatic Impairment Compared to Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01456663
Recruitment Status : Completed
First Posted : October 21, 2011
Last Update Posted : February 5, 2013
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
This study will assess the pharmacokinetics of AFQ056 in subjects with mild, moderate, severe hepatic impairment compared with healthy control subjects.

Condition or disease Intervention/treatment Phase
Hepatic Impairment Drug: AFQ056 Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 118 participants
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: A Single-dose, Open-label, Parallel Study to Assess the Pharmacokinetics of AFQ056 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Control Subjects
Study Start Date : May 2011
Actual Primary Completion Date : July 2012
Actual Study Completion Date : July 2012

Arm Intervention/treatment
Experimental: AFQ056 Drug: AFQ056



Primary Outcome Measures :
  1. Measure: Profile of Pharmacokinetics of AFQ056 in each subjects groups [ Time Frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 36, 48, 72, 96, 120 hours post-dose ]
    AUClast, AUCinf, Cmax, Tmax, T1/2, CL/F, Vz/F


Secondary Outcome Measures :
  1. Measure: : Number of subjects with adverse event in each group [ Time Frame: From dose administration (day 1) to 13+/- 2 days after the single dose administration ]
    Number and type of adverse events, number and type of findings in standard laboratory results, special laboratory results (Hypothaliamic-pituitary axis, porphyrin profile) electrocardiogram holters, or in vital signs

  2. Measure: Plasma protein binding results of AFQ056 in each groups. [ Time Frame: 2 hours after single dose administration ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Groups 1, 2, 3 and 4 (all subjects)
  • Male and female Caucasian subjects
  • Group 1, 2 and 3 (subjects with hepatic impairment)
  • Subjects must satisfy the criteria for hepatic impairment as evidenced by a Child-Pugh score of A, B or C at screening
  • Group 4 (healthy subjects)
  • Each healthy subject must match in age (±8 years), gender, weight (±15%) to an individual subject with hepatic impairment in group 1, 2 or 3.

Exclusion Criteria:

  • Groups 1, 2, 3 and 4 (all subjects)
  • Use of any tobacco products from 1 week prior to cotinine screening assessments until study completion.
  • Group 1, 2 and 3 (subjects with hepatic impairment)
  • History of drug or alcohol abuse within 3 months prior to screening
  • History or presence of any clinically significant disease of any major system organ class including (but not limited to) cardiovascular, metabolic, renal, neurological or psychiatric diseases within 1 month prior to study drug administration except for hepatic impairment or any other disease associated with this underlying condition.
  • Any surgical or medical condition other than hepatic impairment which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the safety of the study subject in case of participation in the study.
  • History or presence of encephalopathy within 6 months prior screening (except for subjects in Groups 2 and 3).
  • Documented presence of a porto-systemic shunt.
  • Documented presence of esophagus varices (stage III or IV).
  • Group 4 (healthy subjects)
  • History or presence of any clinically significant disease of any major system organ class including (but not limited to) cardiovascular, metabolic, renal, neurological or psychiatric diseases.
  • Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the safety of the study subject in case of participation in the study. History of drug or alcohol abuse within 12 months prior to screening, or evidence of such abuse as indicated by the laboratory assays conducted during screening and baseline.
  • History or presence of hepatitis B or C and/or positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result at screening.

Other protocol-defined inclusion/exclusion criteria may apply


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01456663


Locations
United States, Florida
Novartis Investigative Site
Orlando, Florida, United States, 32809
Germany
Novartis Investigative Site
Berlin, Germany, 10117
Hungary
Novartis Investigative Site
Balatonfured, Hungary, 8230
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals

Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01456663     History of Changes
Other Study ID Numbers: CAFQ056A2123
2011-000748-28 ( EudraCT Number )
First Posted: October 21, 2011    Key Record Dates
Last Update Posted: February 5, 2013
Last Verified: February 2013

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
AFQ056
Hepatic impairment
Hepatic impaired

Additional relevant MeSH terms:
Liver Diseases
Digestive System Diseases